Drug Type Bispecific antibody |
Synonyms- |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-Resistant Prostatic Cancer | Phase 1 | United States | 03 Jun 2025 | |
Endometrial Carcinoma | Phase 1 | United States | 03 Jun 2025 | |
Gastrooesophageal junction cancer | Phase 1 | United States | 03 Jun 2025 | |
HER2-negative breast cancer | Phase 1 | United States | 03 Jun 2025 | |
Non-Small Cell Lung Cancer | Phase 1 | United States | 03 Jun 2025 | |
Ovarian Epithelial Carcinoma | Phase 1 | United States | 03 Jun 2025 | |
Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 03 Jun 2025 | |
Squamous Cell Carcinoma of Head and Neck | Phase 1 | United States | 03 Jun 2025 | |
Triple Negative Breast Cancer | Phase 1 | United States | 03 Jun 2025 | |
Urothelial Carcinoma of the Urinary Bladder | Phase 1 | United States | 03 Jun 2025 |